- Last 7 days
-
connect.apollo.roche.com connect.apollo.roche.com
-
2l34IbrutinibAnastrozole,IbrutinibAcalabrutinibAcalabrutinib,Anastrozole2l
Add notation here that If 2l then LOT2Linename == LOTENDS
-
- Apr 2024
-
connect.apollo.roche.com connect.apollo.roche.com
-
Lot 1 Linename
Add any median
-
Mean Second Dos
Median IQR
-
Missing MG First Order
WIthin 45 Days N=
-
-
connect.apollo.roche.com connect.apollo.roche.com
-
LL order details (13%, N=36 now represented in the table)
Updated to reflect 13% not N=13
-
osing Information on Venentoclax Patients
Arliene and Sophia: We only have 273 of our patients with a record in the Medication orders table. Not everyone is represented.
-
-
connect.apollo.roche.com connect.apollo.roche.com
-
UGH
I am aware of typo I will update when I finish Sankey plot. As you can see this report takes 58 minutes to generate.
-
- Dec 2023
-
connect.apollo.roche.com connect.apollo.roche.com
-
OD, N = 19,987,1801 OS, N = 19,940,3591
No need to break eyes.
-
5 Table 3 - Procedures Medication and Drug Tables
Only keep visits that match from Eye table. Check this.
-
N = 3,616,7511
Robert confirm if this is visits or patients
-
- Nov 2023
-
connect.apollo.roche.com connect.apollo.roche.com
-
N of Patient Eyes (1 or 2 Treated)
David, here is the context. We have 83% of patients being treated for both eyes. That will mean that the N of injections probably appears higher since we aren't breaking them down into injections by specific eye.
-
- Oct 2023
-
connect.apollo.roche.com connect.apollo.roche.com
-
Race/Ethnicity (Raw)
Possible project for Sophia? D&I - looking at disparities in ttt
-
VenG vs. Nibs - Tables & Curves - Two to One Match
Removed the 1:1 match - consolidated tables to be based on each matching pair.
-
2 Table 1 Characteristics
Overall Cohort - Moved everything descriptive of overall cohort to this first section
-
Our final sample size for the CLL FlatIron data set is 5,108 CLL patients fitting our inclusion and exclusion criteria.
Final sample size for our study
-
- Sep 2023
-
connect.apollo.roche.com connect.apollo.roche.com
-
Dry AMD 43 (23%)
Is this an artifact of how they are recording the DX.
-
Showing 1 to 2 of 2 entries
Add in a count of the N of Study Patients and N of Sample Patients
-
Missing 0 (0%)
Missing added as a future proof option for future data uploads.
-
OU 0 (0%) Not Recorded 0 (0%)
When we filter out records for condition == ALL we lose all Not Recorded and OU records in the Eye table.
-
-
connect.apollo.roche.com connect.apollo.roche.com
-
Unspecified
Patients with a race value, but it is not useful for analysis. I am considering this missing if we have unspecified. Do you want me to keep it like that?
-
Medicare Cost 497 (0.9%) 1,005 (1.8%) Medicare Risk 3,136 (5.4%) 4,952 (9.0%)
Slightly higher Medicare Cost and Risk patients in the Race/Ethnicity grouping. Possibly due to the older age
-
46 (36, 55) 50 (42, 58)
Fairly significant difference here. Not missing is older in comparison.
-
-
connect.apollo.roche.com connect.apollo.roche.com
-
Months Enrollment Coverage 19 (12, 28) 24.3 (17.2, 29.4
Hmm this seems strange. Can you explain how this was calculated?
-
Age at Enspryng Initiation 47 (32, 55) 47 (30, 52)
Makes sense to me. Looks to be similar across cohorts
-
Ultimately, after consulting with my TI colleagues and reviewing what we need to do for variable follow-up, I believe that for ease of interpretability that we should use the 6 months CE pre patients only for this analysis.
Can you clarify?
-